You are here
XFIBRA, LLC
UEI: D26NRF445JV3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
TREATMENT OF LUNG FIBROSIS: IND PHARMACOLOGY AND TOXICOLOGY
Amount: $1,326,982.00Activation of lung myofibroblasts (LMF) of different origins is responsible for the development of lung fibrosis in in IPF and remarkably, LMF clearance by apoptosis may prevent development of lung fi ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY
Amount: $1,136,111.00Activation of liver myofibroblasts (LMF) of different origins is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, LMF clearance by apoptosis ma ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
TREATMENT OF LUNG FIBROSIS: IND PHARMACOLOGY AND TOXICOLOGY
Amount: $224,967.00Activation of lung myofibroblastsLMFof different origins is responsible for the development of lung fibrosis in in IPF and remarkablyLMF clearance by apoptosis may prevent development of lung fibrosis ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY
Amount: $214,260.00Activation of liver myofibroblastsLMFof different origins is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkablyLMF clearance by apoptosis may prev ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
Amount: $316,111.00DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by ...
STTRPhase I2015Department of Health and Human Services National Institutes of Health -
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS
Amount: $311,803.00DESCRIPTION (provided by applicant): Activation of lung myofibroblasts (LMF) is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably, LMF clearance by ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS
Amount: $306,899.00DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearan ...
STTRPhase I2013Department of Health and Human Services National Institutes of Health
